Kisqali Plus Endocrine Therapy Reduces Breast Cancer Recurrence by 28.5% in Phase 3 Trial
Key Insights
Novartis' Kisqali, combined with endocrine therapy (ET), significantly reduced the risk of breast cancer recurrence by 28.5% in patients with stage II or III HR+/HER2- early breast cancer compared to ET alone.
The Phase 3 clinical trial data showed a sustained benefit beyond the three-year treatment period, offering a potential new treatment option for patients at risk of recurrence.
Novartis has submitted these results to the FDA and EMA, with an FDA decision on approval for this treatment anticipated this quarter, marking a potential advancement in breast cancer therapy.

Stay Updated with Our Daily Newsletter
Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.